Senti Biosciences (NASDAQ:SNTI) Shares Down 8.7%

Senti Biosciences, Inc. (NASDAQ:SNTI)’s share price dropped 8.7% during trading on Monday . The company traded as low as $0.27 and last traded at $0.28. Approximately 91,570 shares traded hands during trading, a decline of 16% from the average daily volume of 108,970 shares. The stock had previously closed at $0.31.

Senti Biosciences Stock Down 8.7 %

The stock has a market cap of $12.85 million, a PE ratio of -0.18 and a beta of 2.96. The stock has a 50-day moving average of $0.39 and a 200 day moving average of $0.41.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) EPS for the quarter. Senti Biosciences had a negative return on equity of 74.59% and a negative net margin of 2,692.82%. Research analysts forecast that Senti Biosciences, Inc. will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Senti Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. TD Asset Management Inc increased its stake in Senti Biosciences by 88.4% during the third quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock worth $102,000 after acquiring an additional 113,172 shares during the last quarter. ARK Investment Management LLC increased its stake in Senti Biosciences by 7.9% during the fourth quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock worth $1,300,000 after acquiring an additional 143,785 shares during the last quarter. Finally, 8VC GP I LLC acquired a new stake in Senti Biosciences during the fourth quarter worth $1,675,000. Institutional investors and hedge funds own 25.73% of the company’s stock.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.